In Brca1-deficient mouse models of ovarian cancer for example, inhibition of CTLA-4 but not PD-1/PD-L1 synergised with PARP inhibitor treatment (Higuchi et al, 2015). This evidence concerns the gene PARP1 and ovarian carcinoma.